Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.240
-0.080 (-2.41%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Cellectis Revenue
Cellectis had revenue of $6.90M in the quarter ending June 30, 2026, a decrease of -62.05%. This brings the company's revenue in the last twelve months to $63.82M, up 594.26% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$63.82M
Revenue Growth
+594.26%
P/S Ratio
3.71
Revenue / Employee
$278,703
Employees
229
Market Cap
236.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
| Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
| Dec 31, 2016 | 56.45M | -6.12M | -9.78% |
| Dec 31, 2015 | 62.57M | 30.56M | 95.47% |
| Dec 31, 2014 | 32.01M | 14.51M | 82.92% |
| Dec 31, 2013 | 17.50M | -10.25M | -36.93% |
| Dec 31, 2012 | 27.74M | 7.04M | 34.00% |
| Dec 31, 2011 | 20.70M | -248.54K | -1.19% |
| Dec 31, 2010 | 20.95M | 6.11M | 41.19% |
| Dec 31, 2009 | 14.84M | -2.65M | -15.16% |
| Dec 31, 2008 | 17.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Invivyd | 58.37M |
| Atrium Therapeutics | 35.84M |
| Adagene | 9.29M |
| Sol-Gel Technologies | 1.80M |
| Veraxa Biotech AG | 29.54K |
CLLS News
- 1 day ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 4 weeks ago - Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline - Nasdaq
- 4 weeks ago - Cellectis reports Q2 adjusted EPS (35c) vs (40c) last year - TheFly
- 4 weeks ago - Cellectis Reports Financial Results for the Second Quarter 2026 - GlobeNewsWire
- 4 weeks ago - Cellectis Earnings release: H1 2026 - Filings
- 4 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 5 weeks ago - Cellectis to Report Second Quarter Financial Results on August 6, 2026 - GlobeNewsWire
- 7 weeks ago - Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio - GlobeNewsWire